At a glance
ClinicalIndex Comparison RecordN/ACompleted· 600 enrolled
Drug / intervention
Terumo SurFlash Plus catheter +1 moredevice
Likely dose
Not stated in record
Key inclusion· 3
- ✓Adult ED patient requiring an IV for clinical care
- ✓Hemodynamically stable with pulse >50 and <130, MAP >60
- ✓Willing to read (or be read to) the informed consent and participate in study
Key exclusion· 4
- ✕Medically unstable
- ✕Agitated or psychiatrically unstable
- ✕Lacking capacity to consent, such as with altered mental status
- ✕Unable to speak and read English
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED
In Brief
A clinical study evaluating Terumo SurFlash Plus catheter and BD Insyte Autoguard catheter for Catheters and Catheterization, Peripheral. Completed, enrolled 600 participants across 1 site.
Detailed Summary
A randomized prospective comparison of two FDA approved intravenous catheters in the emergency department setting. The Terumo SurFlash Plus offers novel technologies that promise to increase intravenous access success rates and decrease blood contamination of the insertion site. This study would analyze these properties in our busy, urban emergency department setting where time and safety of intravenous access are most critical.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCatheters, Catheterization, Peripheral
CountriesUnited States
CollaboratorsTerumo Medical Corporation
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJun 2016
Primary CompletionOct 2016
TodayJul 2026
First PostedMay 11, 2016
Enrollment StartJun 1, 2016
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.1 years ago
Interventions
Terumo SurFlash Plus catheterdevice
BD Insyte Autoguard catheterdevice